Skip to content
NYSE · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP

Volitionrx Ltd. VNRX

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.7M
▲ 40.0% YoY
$-23.4M
$-19.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 1.7M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.7 · Net income -23.4
-15M-30M
201120142017202020232025
Compound annual growth
+78.0%
+164.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +164.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−1361 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1258.5%
-50000%-100000%-150000%
201120182025
ROE
FY2021 · ROE -158.7%
-500%-1000%-1500%
201120182025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -19.8
-10M-20M
201120182025
Net buybacks $M Dividends $M
FY2024 · Dividends · · Net buybacks -8.6
-10M-20M
202220232024

Total assetsUSD 6.9M
EquityUSD -34.2M
CashUSD 1.1M
Gross debtUSD 6.7M
Net debtUSD 5.6M
Current ratio0.17×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VNRX, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.0◌◌◌◌0.0◌0.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B◌◌◌◌◌◌◌◌◌◌−0.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌−0.31−0.50◌−0.51−0.45−0.41−0.57−0.56−0.52−0.54−0.61−0.34−0.44−0.45
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %————−158.7−133.8−122.2−163.0−94.9−87.5−297.2−1566.2−490.0−424.7−239.5
Shares out B0.130.100.080.060.050.050.040.040.030.030.020.010.010.010.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 57 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. Eight checks were skipped: the balance sheet is not tagged before 2011. Five checks were skipped: the share count is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image